Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer cells undergo transformation via reactive oxygen species (ROS) and altered glycolysis.
• This transformation is associated with tumorigenesis and resistance to cancer therapies.
• Targeting regulators of ROS and glycolysis is crucial for developing new cancer therapeutics.

Purpose of the Study:

• To investigate the efficacy of Smac mimetic AZ58 in combination with tumor necrosis factor-α (TNF-α) in inhibiting cancer cell transformation.
• To elucidate the molecular mechanisms underlying the anti-transformation effects, focusing on ROS, glycolysis, and Pim-1 kinase.
• To identify potential therapeutic strategies targeting cancer cell transformation.

Main Methods:

• Treatment of cancer cells with Smac mimetic AZ58 and TNF-α.
• Assessment of reactive oxygen species (ROS) production.
• Analysis of glycolysis and mitochondrial function.
• Investigation of Pim-1 kinase activity and its downstream targets (e.g., BAD phosphorylation).
• Identification of Pim-1 kinase degradation pathways involving caspase-3.

Main Results:

• The combination of AZ58 and TNF-α significantly inhibited ROS production and glycolysis.
• This combination led to Ser-112 phosphorylation of BAD mediated by Pim-1 kinase, increasing mitochondrial depolarization.
• Mitochondrial isoforms of Pim-1 kinase were degraded by AZ58/TNF-α or AZ58/FasL/CHX via caspase-3.
• The treatment effectively blocked cancer cell transformation.

Conclusions:

• Smac mimetic AZ58 combined with TNF-α is a potent therapeutic candidate for blocking cancer cell transformation.
• This combination targets Pim-1 expression, inhibits ROS production, and disrupts glycolysis.
• The findings provide a novel therapeutic approach by targeting key regulators of cancer cell plasticity.